[go: up one dir, main page]

NO20076121L - Behandlinger for kardiovaskulaer sykdom - Google Patents

Behandlinger for kardiovaskulaer sykdom

Info

Publication number
NO20076121L
NO20076121L NO20076121A NO20076121A NO20076121L NO 20076121 L NO20076121 L NO 20076121L NO 20076121 A NO20076121 A NO 20076121A NO 20076121 A NO20076121 A NO 20076121A NO 20076121 L NO20076121 L NO 20076121L
Authority
NO
Norway
Prior art keywords
treatments
cardiovascular disease
agents
methods
cardiac dysfunction
Prior art date
Application number
NO20076121A
Other languages
English (en)
Inventor
David Y Liu
Ingrid Langsetmo Parobok
Christopher T Jacob
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NO20076121L publication Critical patent/NO20076121L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Den foreliggende oppfinnelsen gjelder fremgangsmåter og midler for behandling av svekket karfunksjon og hjertefunksjon. Fremgangsmåter og midler for behandling av forskjellige fysiologiske og patologiske tilstander forbundet med kardysfunksjon og hjertedysfunksjon tilveiebringes også.
NO20076121A 2005-05-05 2007-11-27 Behandlinger for kardiovaskulaer sykdom NO20076121L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67849505P 2005-05-05 2005-05-05
US69095705P 2005-06-15 2005-06-15
US73443305P 2005-11-07 2005-11-07
PCT/US2006/017760 WO2006122047A1 (en) 2005-05-05 2006-05-05 Cardiovascular disease therapies

Publications (1)

Publication Number Publication Date
NO20076121L true NO20076121L (no) 2008-02-04

Family

ID=36778299

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20076121A NO20076121L (no) 2005-05-05 2007-11-27 Behandlinger for kardiovaskulaer sykdom
NO20076241A NO20076241L (no) 2005-05-05 2007-12-04 Terapier for vaskulaere sykdommer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20076241A NO20076241L (no) 2005-05-05 2007-12-04 Terapier for vaskulaere sykdommer

Country Status (10)

Country Link
US (3) US8088381B2 (no)
EP (2) EP1891109A1 (no)
JP (2) JP2008540456A (no)
AU (2) AU2006244147A1 (no)
CA (2) CA2607044A1 (no)
IL (2) IL187115A0 (no)
MX (2) MX2007013834A (no)
NO (2) NO20076121L (no)
NZ (1) NZ563493A (no)
WO (2) WO2006122046A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098065A2 (en) * 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US9050350B2 (en) 2007-10-18 2015-06-09 U.S. Department Of Veterans Affairs Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk
US9114151B2 (en) * 2007-10-18 2015-08-25 The United States Of America Dept. Of Veterans Affairs Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
US9220720B2 (en) 2007-10-18 2015-12-29 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
US9211301B2 (en) 2007-10-18 2015-12-15 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN103429270B (zh) 2008-08-25 2016-11-23 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
WO2010032007A1 (en) * 2008-09-18 2010-03-25 Universitetet I Oslo Use of ctgf as a cardioprotectant
US20110262398A1 (en) * 2010-04-21 2011-10-27 University Of Illinois Cardiac treatment using anti-fibrotic agents
KR101249041B1 (ko) * 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
US9173894B2 (en) 2011-02-02 2015-11-03 Excaliard Pharamaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
DE102012103096A1 (de) * 2012-04-11 2013-10-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Prophylaxe und Behandlung einer Gefäßkalzifizierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
JPH11180895A (ja) 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
AU1682699A (en) * 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US20010006979A1 (en) 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
EP1140964B1 (en) 1998-12-14 2008-04-09 University Of Miami Connective tissue growth factor (ctgf) fragment
JP2004502644A (ja) * 2000-03-09 2004-01-29 ジェンザイム、コーポレーション 腎機能の喪失を治療または予防するためのＴＧＦ−β拮抗薬の使用
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US20030153524A1 (en) * 2001-12-11 2003-08-14 Hinton David R. Methods for inhibiting ocular processes
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050214294A1 (en) 2004-02-11 2005-09-29 Allan Flyvbjerg Diabetic nephropathy therapies

Also Published As

Publication number Publication date
JP2008540456A (ja) 2008-11-20
WO2006122046A3 (en) 2007-05-31
US8088381B2 (en) 2012-01-03
MX2007013819A (es) 2008-02-05
AU2006244147A1 (en) 2006-11-16
EP1885756A2 (en) 2008-02-13
EP1891109A1 (en) 2008-02-27
JP5068253B2 (ja) 2012-11-07
WO2006122047A1 (en) 2006-11-16
AU2006244148A1 (en) 2006-11-16
WO2006122046A2 (en) 2006-11-16
IL187113A0 (en) 2008-02-09
NZ563493A (en) 2010-10-29
US20060281668A1 (en) 2006-12-14
CA2606778A1 (en) 2006-11-16
MX2007013834A (es) 2008-02-05
JP2008540457A (ja) 2008-11-20
NO20076241L (no) 2008-02-04
US20060281667A1 (en) 2006-12-14
IL187113A (en) 2011-06-30
IL187115A0 (en) 2008-02-09
US20120039882A1 (en) 2012-02-16
CA2607044A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
NO20034590D0 (no) Fremgangsmåter for behandling av vaskul¶r sykdom
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
WO2002038794A3 (en) Cardiovascular disease diagnostic and therapeutic targets
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EP1532269A4 (en) 1L1RL-1 AS A MARKER FOR CARDIOVASCULAR DISEASES AND THERAPEUTIC TARGET
EA200970360A1 (ru) Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
WO2009149106A3 (en) Microparticles for the treatment of disease
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
NO20076405L (no) Anvendelse av 24-nor-UDCA
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
NO20070996L (no) Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser
WO2005062958A3 (en) Meth0ds of using hcn genes to treat cardiac arrhythmias
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
WO2006109170A3 (en) Combination therapy for treatment of cardiovascular diseases and related conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application